Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia. Agios on ...

Thalassemia is a common genetic condition affecting red blood cells. Children with severe forms of thalassemia often develop symptoms early in life, but effective treatment can manage the condition.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

Iron deficiency anemia (IDA) and thalassemia represent two of the most prevalent causes of microcytic anemia worldwide. Effective screening is critical not only to guide appropriate treatment — as IDA ...

Investigators used MRI to evaluate brain perfusion in patients with transfusion-dependent (n=54) and non–transfusion-dependent (n=23) β-thalassemia versus 56 controls. They found that relative ...

The autors present a study in 268 children (154 diagnosed with thalassemia trait and 112 diagnosed with iron deficiency anemia), ranged from 6 month to 18 years, in Pediatric Department, Clinical ...

The thalassemia market is primarily driven by regular blood transfusions and iron chelation therapies, which help manage anemia and prevent iron overload. Curative treatments, such as stem cell ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

The effects of variations in α-gene numbers on phenotypical expression of β-thalassemia are assessed in 11 subjects of 8 families. The study indicates that coexistence of α-thalassemia (–α3.7/αα) ...

AAPI Nexus: Asian Americans and Pacific Islanders, Policy, Practice and Community, Vol. 4, No. 2, Youth (Summer/Fall 2006), pp. 111-134 (24 pages) Thalassemia is a potentially life-threatening genetic ...

Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in ...